Table 5.
SN, SP, PPV, and NPV of CA125, HE4, ROMA, and CPH-I in differentiating BOT I+II from EOC I+II group stratification by pathology.
| Menopausal status | SN (%) | SP (%) | PPV (%) | NPV (%) |
|---|---|---|---|---|
| Serous | ||||
| HE4 | 76.74 | 90.11 | 78.57 | 89.13 |
| CA125 | 60.47 | 75.82 | 54.17 | 80.23 |
| ROMA | 79.07 | 86.81 | 73.91 | 89.77 |
| CPH-I | 83.72 | 74.73 | 61.00 | 90.70 |
| Mucinous | ||||
| HE4 | 70.00 | 85.00 | 53.85 | 91.89 |
| CA125 | 70.00 | 72.50 | 38.89 | 90.63 |
| ROMA | 70.00 | 80.00 | 53.33 | 91.43 |
| CPH-I | 90.00 | 67.50 | 40.90 | 96.40 |
| Endometrioid | ||||
| HE4 | 39.13 | 100 | 100 | 39.13 |
| CA125 | 52.17 | 77.78 | 85.71 | 38.89 |
| ROMA | 43.48 | 100 | 100 | 40.91 |
| CPH-I | 65.22 | 77.78 | 88.20 | 46.70 |
Abbreviations: SN = sensitivity; SP = specificity; PPV = positive predictive value; NPV = negative predictive value; BOT I+II = borderline ovarian tumors in FIGO stages I and II; EOC I+II = epithelial ovarian cancer in FIGO stages I and II.